NASDAQ
3.68USD
+0.19 (+5.44%)
We have scored 7 news catalysts on Immuneering Corporation (IMRX) over the past 12 months. The biggest single-day move next to one of them came Jan 8, 2026, when IMRX closed −43.2%: “Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data”. Coverage across the window leans positive (average ticker sentiment +0.61). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
238.3M
P/E
—
EPS
—
Beta
0.39
52W range
3.38-8.48
Day range
3.52–3.76
Open
3.52
Prev close
3.49
Volume
877.9K
Avg volume
852.3K
Dividend
0.00
IPO
2021-07-30
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Immuneering Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for IMRX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
